Shanghai Hengrui Pharmaceutical Co., Ltd. Drug Pipeline

Shanghai Hengrui Pharmaceutical Co., Ltd. maintains a substantial clinical development portfolio, with 48 trials registered since 2008, including 30 currently active. The pipeline spans from Phase 1 through Phase 3, with 21 active programs in Phase 1, 20 in Phase 2, and 2 in Phase 3. Clinical activity is heavily concentrated in oncology, which accounts for 23 active trials, or 77% of the total active portfolio. Beyond oncology, the company also has active trials in pain, CNS, and respiratory indications. Within oncology, the most active indications are advanced solid tumors, with 13 active trials, followed by NSCLC and bladder cancer, with 3 active trials each. One Phase 3 trial is ongoing in bladder cancer. Additional oncology programs are investigating multiple myeloma and pancreatic cancer. The portfolio's strong focus on early-phase oncology programs suggests a long-term strategic emphasis in this therapeutic area.